Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.930
+0.073 (8.47%)
At close: Jan 21, 2025, 4:00 PM
0.896
-0.034 (-3.62%)
After-hours: Jan 21, 2025, 7:35 PM EST
Cosmos Health Revenue
Cosmos Health had revenue of $12.41M in the quarter ending September 30, 2024, a decrease of -3.22%. This brings the company's revenue in the last twelve months to $56.04M, up 13.01% year-over-year. In the year 2023, Cosmos Health had annual revenue of $53.38M with 6.02% growth.
Revenue (ttm)
$56.04M
Revenue Growth
+13.01%
P/S Ratio
0.28
Revenue / Employee
$455,627
Employees
123
Market Cap
19.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
Dec 31, 2019 | 39.68M | 2.59M | 6.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
COSM News
- 13 hours ago - Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days - Accesswire
- 8 days ago - Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Accesswire
- 26 days ago - Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology - Accesswire
- 4 weeks ago - Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000 - Accesswire
- 2 months ago - Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets - Accesswire
- 2 months ago - Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M - Accesswire
- 2 months ago - Cosmos Health Issues Letter to Shareholders - Accesswire
- 2 months ago - Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% - Accesswire